Clinical trials: Injection Complication
Diabetic Nephropathies, Peripheral Nervous System Diseases
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects.
- Trial name
- NCT02552277
- Testing
- PDA-002
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Celularity Incorporated
IgA Nephropathy
Study of CM313 in Subject With IgA Nephropathy
This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK)…
- Trial name
- NCT06830395
- Testing
- CM313
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Keymed Biosciences Co.Ltd
Recurrent or Metastatic Cervical Cancer
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
- Trial name
- NCT07051486
- Testing
- SHR-A1811 Injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Female Infertility
Recombinant Follicle-stimulating Hormone in Treatment for Infertility
This is a randomized multi-centre, assessor-blind, parallel-group study to be conducted in 250 women in the age group of 20 to 39 years (both inclusive), who are indicated to undergo COS as part of assisted reproductive…
- Trial name
- REFRESH (NCT05266924)
- Testing
- Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Bharat Serums and Vaccines Limited
Ovarian Cancer
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
The standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance.
- Trial name
- NCT04908787
- Testing
- BD0801, Paclitaxel, Topotecan
- Where
- 55 sites in China
- Volunteers
- 421 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd
Infertility, Female
Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers
The goal of this Interventional study is to Compare the Pharmacokinetics and Safety of Recombinant Human Follicle Stimulating Hormone Injection (QL1012D) and Gonal-F® in Healthy Female Volunteers.
- Trial name
- NCT06864793
- Testing
- QL1012D, Gonal-F®
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer and Ovarian Cancer
Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.
- Trial name
- NCT03055143
- Testing
- SPARC-08-038, Ref-08-038
- Volunteers
- 29 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed/refractory solid tumor malignancies…
- Trial name
- NCT03323398
- Testing
- mRNA-2416, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- ModernaTX, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
- Trial name
- NCT03835884
- Testing
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Aerie Pharmaceuticals
Secondary Hyperparathyroidism, End Stage Renal Disease
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
- Trial name
- NCT00053547
- Testing
- paricalcitol injection
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Abbott